NDAORALTABLET
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SINE-AID IB is an oral tablet combination of ibuprofen (NSAID) and pseudoephedrine HCl (decongestant) approved in 1992 for symptomatic relief of sinus congestion, pain, and pressure associated with sinusitis and the common cold. The ibuprofen component reduces inflammation and pain while pseudoephedrine constricts nasal blood vessels to relieve congestion. This is a mature OTC/OTC-equivalent product in the cold and sinus symptom relief category.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling likely consolidation or transition planning for associated brand teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SINE-AID IB offers limited career expansion opportunities given its mature, LOE-approaching lifecycle and zero linked job openings. Roles are primarily focused on defensive brand management, retail partnerships, and channel optimization rather than innovation or growth.
Brand ManagerField Sales Representative
Worked on SINE-AID IB at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.